Abstract:There is still no effective drug treatment available for Charcot-Marie-Tooth disease (CMT). Current management relies on rehabilitation therapy, surgery for skeletal deformities, and symptomatic treatment. The challenge is to find disease-modifying therapies. Several approaches, including gene silencing (by means of ASO, siRNA, shRNA, miRNA, CRISPR-Cas9 editing), to counteract the PMP22 gene overexpression in the most frequent CMT1A type are under investigation. PXT3003 is the compound in the most advanced phase for CMT1A, as a second phase-III trial is ongoing. Gene therapy to substitute defective genes (particularly in recessive forms associated with loss-of-function mutations) or insert novel ones (e.g., NT3 gene) are being developed and tested in animal models and in still exceptional cases have reached the clinical trial phase in humans. Novel treatment approaches are also aimed at developing compounds acting on pathways important for different CMT types. Modulation of the neuregulin pathway determining myelin thickness is promising for both hypo-demyelinating and hypermyelinating neuropathies; intervention on Unfolded Protein Response seems effective for rescuing misfolded myelin proteins such as MPZ in CMT1B. HDAC6 inhibitors improved axonal transport and ameliorated phenotypes in different CMT models. Other potential therapeutic strategies include targeting macrophages, lipid metabolism, and Nav1.8 sodium channel in demyelinating CMT and the P2×7 receptor, which regulates calcium influx into Schwann cells, in CMT1A. Further approaches are aimed at correcting metabolic abnormalities, including the accumulation of sorbitol caused by biallelic mutations in the sorbitol dehydrogenase (SORD) gene and of neurotoxic glycosphingolipids in HSN1.

Charcot-Marie-Tooth: From Molecules to Therapy

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

Clinical and Genetic Characteristics of Charcot-Marie-Tooth Disease

Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

Charcot-Marie-Tooth Disease: Seventeen Causative Genes

Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

New developments in Charcot-Marie-Tooth neuropathy and related diseases

Advances in the Study of Genetic Characteristics and Molecular Mechanisms in Charcot-Marie-Tooth Disease

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies

Current Treatment Methods for Charcot–Marie–Tooth Diseases

Genetics of Charcot-Marie-Tooth (CMT) Disease within the Frame of the Human Genome Project Success

Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease

[Guidelines for molecular diagnosis of Charcot-Marie-Tooth disease]

Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)

Clinical genetics of Charcot-Marie-Tooth disease

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives

Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches

Next-generation sequencing in Charcot–Marie–Tooth disease: opportunities and challenges

One Multilocus Genomic Variation Is Responsible for a Severe Charcot-Marie-Tooth Axonal Form